Metabolites News and Research

RSS

Novel vaccine for treating heroin addiction

Researchers at The Scripps Research Institute have developed a highly successful vaccine against a heroin high and have proven its therapeutic potential in animal models.

21 Jul 2011

Researchers identify potential therapeutic target for ER-negative breast cancer

Using a new in vivo screening system, Whitehead Institute researchers have identified a protein in the serine biosynthesis pathway that is essential in estrogen receptor (ER)-negative breast cancer—a notoriously difficult disease to treat associated with low five-year survival rates.

19 Jul 2011

Study shows benefits of onion waste on human health

More than 500,000 tonnes of onion waste are thrown away in the European Union each year. However, scientists say this could have a use as food ingredients. The brown skin and external layers are rich in fibre and flavonoids, while the discarded bulbs contain sulphurous compounds and fructans. All of these substances are beneficial to health.

14 Jul 2011

EPO grants patent for Aeterna Zentaris' perifosine to treat benign, malignant tumours

Aeterna Zentaris Inc. today announced that the European Patent Office has granted a patent for the use of alkyl phosphocholines, more specifically perifosine, in the preparation of a medicament for the treatment of benign and malignant tumours, prior to and/or during the treatment with approved anti-tumour anti-metabolites such as 5FU and capecitabine.

12 Jul 2011

Study confirms link between phthalates and thyroid hormone levels in humans

A link between chemicals called phthalates and thyroid hormone levels was confirmed by the University of Michigan in the first large-scale and nationally representative study of phthalates and BPA in relation to thyroid function in humans.

12 Jul 2011

UTMB scientists to look at possible impact of Gulf oil spill on seafood safety

In an effort to determine the vulnerability of affected Gulf Coast communities following last year's BP oil spill,the National Institute of Environmental Health Sciences has awarded a five-year $7.85 million grant to a consortium of university researchers and Gulf Coast community groups led by the University of Texas Medical Branch at Galveston to examine the safety of Gulf seafood and the long-term health of those who consume it.

8 Jul 2011

Sodium intake during pregnancy alters kidney development in offspring

A new animal study from Europe has drawn an association between pregnant mothers' sodium intake and their newborn's kidney development.

7 Jul 2011

Scientists discover three unexpected RNAs involved in diabetes cell-death pathway

Excess nutrients, such as fat and sugar, don't just pack on the pounds but can push some cells in the body over the brink. Unable to tolerate this "toxic" environment, these cells commit suicide.

6 Jul 2011

New insight into tumor biology

Cancer cells are well known for their altered metabolisms, which may help them generate the energy they need for rapid growth. Using an emerging imaging technology, researchers reporting in the July Cell Metabolism, a Cell Press publication, have discovered that those metabolic shifts actually develop even before detectable tumors form.

6 Jul 2011

Novel biomarker-development pipeline approach for human diseases

Researchers at Fred Hutchinson Cancer Research Center have demonstrated in mice that the performance of a novel biomarker-development pipeline using targeted mass spectrometry is robust enough to support the use of an analogous approach in humans.

20 Jun 2011

USPTO issues patent for Predictive Biosciences' multiple biomarker assay

Predictive Biosciences, a provider of novel molecular diagnostic tests, announced that on June 7, 2011 the U.S. Patent and Trademark Office issued Patent Number 7,955,822 for "Detection of Nucleic Acids and Proteins".

17 Jun 2011

Rosa, Profil Institute partner to offer simulation technology for diabetes and obesity clinical trials

Profil Institute for Clinical Research, Inc., a company leading the industry in early phase clinical trials for diabetes and obesity, and Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, jointly announced today a strategic alliance to offer Profil Institute customers use of Rosa's modeling technology to simulate disease physiology, drug action, patient variability, and trial outcomes for their early phase clinical development programs.

8 Jun 2011

Non-steroidal, oral contraceptive for men

Researchers at Columbia University Medical Center are honing in on the development of what may be the first non-steroidal, oral contraceptive for men. Tests of low doses of a compound that interferes with retinoic acid receptors (RARs), whose ligands are metabolites of dietary vitamin A, showed that it caused sterility in male mice.

7 Jun 2011

Waters introduces SYNAPT G2-S at 59th ASMS Conference on Mass Spectrometry

Waters Corporation today introduced the SYNAPT® G2-S High Definition Mass Spectrometer, representing a significant step forward in performance for High Definition Mass Spectrometry. The SYNAPT G2-S incorporates both high-sensitivity Waters StepWave™ ion transfer optics and Triwave® ion mobility technologies along with a suite of new informatics tools to take qualitative and quantitative high resolution performance to a new level.

6 Jun 2011

Medical researchers uncover a novel approach to treat Huntington's disease

Medical researchers may have uncovered a novel approach to treat an incurable and ultimately fatal neurodegenerative disease that affects hundreds of thousands of people.

3 Jun 2011

New slow-release compound protects against Huntington's and Alzheimer's

A study in a special early online publication of Cell, a Cell Press publication, reveals a promising new slow-release compound that protects mice against the neurodegenerative effects of both Huntington's and Alzheimer's disease.

3 Jun 2011

Research provides new understanding of how heroin affects the brain

New research from the Norwegian Institute of Public Health suggests that our understanding of how heroin affects the brain should be changed. A new report shows that heroin is metabolised to 6-MAM which then crosses the blood-brain barrier to cause the intoxicating effects that arise shortly after heroin administration.

27 May 2011

Nordic Naturals' dietary supplements earn NSF certification

Nordic Naturals has earned certification from NSF International, verifying that its new LEED-designed corporate headquarters complies with Good Manufacturing Practices as set forth in NSF/ANSI Standard 173-2008, Dietary Supplements, Section 8.

17 May 2011

Almac launches six enzyme screening kits

As anticipated, Almac's biocatalysis business has expanded from its 2009 launch with the sale of six enzyme screening kits, to the current supply of 100s of kgs of chiral intermediates for drug substance manufacture, regular enzyme supply to specialty chemical companies and continued growth of its screening kits offering. Biocatalysis is increasingly recognised as an alternative solution for solving complex chemistry problems due to its rapid implementation, economic benefits and 'green' reputation.

4 May 2011

JPO issues patent to Silence Therapeutics' RNAi technology

Silence Therapeutics plc announces the issuance of patent 4,705,370, titled "Further Novel Forms of Interfering RNA Molecules," by the Japanese Patent Office.

3 May 2011